176 related articles for article (PubMed ID: 3098121)
1. Inhibition of polyamine biosynthesis by alpha-difluoromethylornithine in African trypanosomes and Pneumocystis carinii as a basis of chemotherapy: biochemical and clinical aspects.
McCann PP; Bacchi CJ; Clarkson AB; Bey P; Sjoerdsma A; Schecter PJ; Walzer PD; Barlow JL
Am J Trop Med Hyg; 1986 Nov; 35(6):1153-6. PubMed ID: 3098121
[TBL] [Abstract][Full Text] [Related]
2. Further studies on difluoromethylornithine in African trypanosomes.
McCann PP; Bacchi CJ; Clarkson AB; Seed JR; Nathan HC; Amole BO; Hutner SH; Sjoerdsma A
Med Biol; 1981 Dec; 59(5-6):434-40. PubMed ID: 6175860
[TBL] [Abstract][Full Text] [Related]
3. Polyamine metabolism: a potential therapeutic target in trypanosomes.
Bacchi CJ; Nathan HC; Hutner SH; McCann PP; Sjoerdsma A
Science; 1980 Oct; 210(4467):332-4. PubMed ID: 6775372
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of lethal protozoal infections with the ornithine decarboxylase inhibitor, alpha-difluoromethylornithine.
Sjoerdsma A; Golden JA; Schechter PJ; Barlow JL; Santi DV
Trans Assoc Am Physicians; 1984; 97():70-9. PubMed ID: 6442954
[No Abstract] [Full Text] [Related]
5. [Treatment of sleeping disease caused by trypanosoma brucei gambiense with alpha-difluoromethylornithine (DFMO) in a rural hospital in Zaire].
De Groof D; Bruneel H; Musumari TS; Ruppol JF
Med Trop (Mars); 1992; 52(4):369-75. PubMed ID: 1494306
[TBL] [Abstract][Full Text] [Related]
6. Pneumocystis carinii pneumonia treated with alpha-difluoromethylornithine. A prospective study among patients with the acquired immunodeficiency syndrome.
Golden JA; Sjoerdsma A; Santi DV
West J Med; 1984 Nov; 141(5):613-23. PubMed ID: 6440364
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
Milord F; Pépin J; Loko L; Ethier L; Mpia B
Lancet; 1992 Sep; 340(8820):652-5. PubMed ID: 1355219
[TBL] [Abstract][Full Text] [Related]
8. [The use of difluoromethylornithine in congenital trypanosomiasis due to Trypanosoma brucei-gambiense].
Pepin J; Guern C; Milord F; Ethier L; Bokelo M; Schechter PJ
Med Trop (Mars); 1989; 49(1):83-5. PubMed ID: 2498607
[TBL] [Abstract][Full Text] [Related]
9. [DFMO: an alternative therapeutic agent for human African trypanosomiasis].
Breton JC; Bouteille B; Sonan T
Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):571-7. PubMed ID: 3143490
[TBL] [Abstract][Full Text] [Related]
10. Effects of polyamines on two strains of Trypanosoma brucei in infected rats and in vitro culture.
Nishimura K; Yanase T; Araki N; Ohnishi Y; Kozaki S; Shima K; Asakura M; Samosomsuk W; Yamasaki S
J Parasitol; 2006 Apr; 92(2):211-7. PubMed ID: 16729674
[TBL] [Abstract][Full Text] [Related]
11. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.
Doua F; Boa FY; Schechter PJ; Miézan TW; Diai D; Sanon SR; De Raadt P; Haegele KD; Sjoerdsma A; Konian K
Am J Trop Med Hyg; 1987 Nov; 37(3):525-33. PubMed ID: 3120607
[TBL] [Abstract][Full Text] [Related]
12. Eflornithine. A new drug in the treatment of sleeping sickness.
Van Bogaert I; Haemers A
Pharm Weekbl Sci; 1989 Jun; 11(3):69-75. PubMed ID: 2505225
[TBL] [Abstract][Full Text] [Related]
13. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness.
Pepin J; Milord F; Guern C; Schechter PJ
Lancet; 1987 Dec; 2(8573):1431-3. PubMed ID: 2891995
[TBL] [Abstract][Full Text] [Related]
14. [A new molecule in antiparasitic therapy: alpha-difluoromethylornithine].
Furet Y; Duong TH; Combescot C; Breteau M
Pathol Biol (Paris); 1987 Apr; 35(4):398-404. PubMed ID: 3108836
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of human trypanosomiasis caused by Trypanosoma brucei gambiense using alpha-difluoromethylornithine. Results in 7 patients].
Taelman H; Marcelis L; Sonnet J; Kazyumba G; Van den Enden E; Wery M; Schechter PJ
Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):578-88. PubMed ID: 3143491
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of DL-alpha-difluoromethylornithine against susceptible and drug-resistant Trypanosoma brucei brucei.
Zweygarth E; Kaminsky R
Acta Trop; 1991 Jan; 48(3):223-32. PubMed ID: 1671624
[TBL] [Abstract][Full Text] [Related]
17. Polyamine metabolism in Pneumocystis carinii.
Lipschik GY; Masur H; Kovacs JA
J Infect Dis; 1991 May; 163(5):1121-7. PubMed ID: 2019760
[TBL] [Abstract][Full Text] [Related]
18. Differential susceptibility to DL-alpha-difluoromethylornithine in clinical isolates of Trypanosoma brucei rhodesiense.
Bacchi CJ; Nathan HC; Livingston T; Valladares G; Saric M; Sayer PD; Njogu AR; Clarkson AB
Antimicrob Agents Chemother; 1990 Jun; 34(6):1183-8. PubMed ID: 2118325
[TBL] [Abstract][Full Text] [Related]
19. Effects of the ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models.
Bacchi CJ; Nathan HC; Clarkson AB; Bienen EJ; Bitonti AJ; McCann PP; Sjoerdsma A
Am J Trop Med Hyg; 1987 Jan; 36(1):46-52. PubMed ID: 3101528
[TBL] [Abstract][Full Text] [Related]
20. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
